Incyte To Stop A Phase 2 Sub-Study, Shares Lose 10%

Incyte CorporationINCYsaid it will stop an ongoing Phase 2 sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP. According to Incyte's press release, the company decided to stop its study after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation. "We are disappointed at the outcome from this interim analysis and deeply grateful for the support and commitment of the patients participating in the study, their families, and the study investigators," said Steven Stein, M.D., Chief Medical Officer of Incyte.